ADC Therapeutics SA (ADCT) shareholders
Close on Nov 17, 2026Market cap $172.35MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Redmile Group, LLC Joint filing with Jeremy C. Green (14.00%), RedCo II Master Fund, L.P. (11.70%) | 15,666,731 | 14.00% | 13G (passive) amendment | Jun 30, 2025 |
| Bain Capital Life Sciences Opportunities IV, L.P. | 14,825,625 | 9.99% | 13G (passive) | Oct 22, 2026 |
| Jeremy C. Green Joint filing with Redmile Group, LLC (9.90%), RedCo II Offshore SPV LLC (6.10%) | 12,717,487 | 9.90% | 13G (passive) amendment | Apr 20, 2026 |
| Daniel Mack Joint filing with Nantahala Capital Management, LLC (9.69%), Wilmot B. Harkey (9.69%) | 12,326,184 | 9.69% | 13G (passive) | Jun 30, 2026 |
| TCG Crossover GP II, LLC Joint filing with TCG Crossover Fund II, L.P. (9.20%), Chen Yu (9.20%) | 11,390,175 | 9.20% | 13G (passive) | Oct 27, 2025 |
| Dr. Hans-Peter Wild Joint filing with Hpwh Th AG (8.52%) | 9,788,944 | 9.61% | 13G (passive) amendment | May 15, 2025 |
| W. Lawrence Hawkins Joint filing with Prosight Management, LP (6.80%), Prosight Partners, LLC (6.80%) | 8,477,338 | 6.80% | 13G (passive) amendment | Dec 31, 2025 |
| Prosight Management, LP Joint filing with Prosight Partners, LLC (5.80%), W. Lawrence Hawkins (5.80%) | 7,195,374 | 5.80% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 6,857,815 | 5.40% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ADCT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 24,652,368 | 19.31% | $26.38M | +19,054,935 | 0.44% |
| Redmile Group, LLC | 11,526,710 | 9.03% | $12.33M | −3,943,792 | 0.83% |
| TCG Crossover Management, LLC | 11,390,175 | 8.92% | $12.19M | – | 0.29% |
| Prosight Management, LP | 7,824,749 | 6.13% | $8.37M | −475,251 | 1.44% |
| BlackRock, Inc. | 7,020,093 | 5.50% | $7.51M | +769,346 | 0.00% |
| Point72 Asset Management, L.P. | 3,649,144 | 2.86% | $3.90M | +267,015 | 0.00% |
| Morgan Stanley | 3,051,173 | 2.39% | $3.26M | −761,409 | 0.00% |
| Millennium Management LLC | 2,899,535 | 2.27% | $3.10M | −219,619 | 0.00% |
| Citadel Advisors LLC | 2,053,316 | 1.61% | $2.20M | +1,653,595 | 0.00% |
| Goldman Sachs Group Inc | 1,914,424 | 1.50% | $2.05M | +261,398 | 0.00% |
| State Street Corp | 1,685,836 | 1.32% | $1.80M | +119,174 | 0.00% |
| Geode Capital Management, LLC | 1,445,546 | 1.13% | $1.55M | +241,790 | 0.00% |
| Bank Of America Corp /De/ | 1,288,206 | 1.01% | $1.38M | −36,811 | 0.00% |
| Vanguard Portfolio Management LLC | 897,092 | 0.70% | $959.89K | −136,185 | 0.00% |
| Two Sigma Investments, LP | 773,414 | 0.61% | $827.55K | +105,392 | 0.00% |
| Blue Owl Capital Holdings LP | 733,568 | 0.57% | $784.92K | – | 0.12% |
| D. E. Shaw & Co., Inc. | 719,320 | 0.56% | $769.67K | +476,144 | 0.00% |
| Opaleye Management Inc. | 700,000 | 0.55% | $749.00K | New | 0.07% |
| Aqr Capital Management LLC | 658,125 | 0.52% | $704.19K | +420,488 | 0.00% |
| Bnp Paribas Arbitrage, Snc | 652,849 | 0.51% | $698.55K | −207,642 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 114 | 93M | 72.9% | 27 / 42 | 30 / 30 | 26M | 16M |
| Q1 2026 | 118 | 84M | 65.4% | 19 / 52 | 29 / 14 | 10M | 8M |
| Q4 2025 | 115 | 83M | 64.9% | 21 / 48 | 28 / 12 | 23M | 8M |
| Q3 2025 | 106 | 68M | 53.4% | 23 / 30 | 23 / 3 | 9M | 8M |
| Q2 2025 | 86 | 68M | 53.2% | 14 / 17 | 39 / 10 | 15M | 2M |
| Q1 2025 | 82 | 55M | 43.0% | 13 / 27 | 20 / 13 | 2M | 3M |
| Q4 2024 | 83 | 56M | 44.3% | 16 / 33 | 16 / 10 | 7M | 6M |
| Q3 2024 | 77 | 55M | 43.1% | 19 / 33 | 10 / 14 | 10M | 3M |
| Q2 2024 | 74 | 52M | 40.6% | 45 / 12 | 7 / 8 | 20M | 8M |
| Q1 2024 | 37 | 40M | 31.4% | 11 / 7 | 9 / 12 | 10M | 4M |
| Q4 2023 | 38 | 35M | 27.2% | 8 / 7 | 10 / 11 | 4M | 9M |
| Q3 2023 | 41 | 39M | 30.9% | 4 / 14 | 13 / 18 | 2M | 7M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ameet Mallik | Chief Executive Officer, Director | 2,790,870 | 2.19% | Jul 2, 2026 |
| Mohamed Zaki | Chief Medical Officer | 896,317 | 0.70% | Jul 2, 2026 |
| Peter J. Graham | Chief Legal Officer | 841,640 | 0.66% | Jul 2, 2026 |
| Jose Carmona | Chief Financial Officer | 938,076 | 0.73% | Jul 2, 2026 |
| Lisa Michelle Kallebo | Chief Accounting Officer | 128,224 | 0.10% | Feb 18, 2026 |
| Viviane Monges | Director | 186,447 | 0.15% | Jun 3, 2026 |
| Victor Sandor | Director | 140,686 | 0.11% | Jun 3, 2026 |
| Robert Azelby | Director | 112,805 | 0.09% | Jun 3, 2026 |
| Timothy Coughlin | Director | 72,400 | 0.06% | Jun 3, 2026 |
| Jean-Pierre Bizzari | Director | 139,302 | 0.11% | Jun 3, 2026 |
| Ron Squarer | Director | 123,431 | 0.10% | Jun 3, 2026 |
| Peter Hug | Director | 263,344 | 0.21% | Jun 3, 2026 |
| Jeremy Green | 10% owner | 28,812,443 | 22.57% | Apr 2, 2026 |
| RedCo II Master Fund, L.P. | 10% owner | 38,233,265 | 29.95% | Apr 2, 2026 |
| Redmile Group, LLC | 10% owner | 27,864,257 | 21.83% | Apr 2, 2026 |
| Thomas Pfisterer | – | 625,755 | 0.49% | May 19, 2025 |
| Hans Peter Wild | 10% owner | 9,788,944 | 7.67% | May 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ameet Mallik Chief Executive Officer, Director | Jun 30, 2026 | Award | +675,000 | – | – | 2,121,769 |
| Peter J. Graham Chief Legal Officer | Jun 30, 2026 | Award | +221,100 | – | – | 841,640 |
| Mohamed Zaki Chief Medical Officer | Jun 30, 2026 | Award | +213,900 | – | – | 896,317 |
| Jose Carmona Chief Financial Officer | Jun 30, 2026 | Award | +203,700 | – | – | 938,076 |
| Timothy Coughlin Director | Jun 3, 2026 | Tax withholding | −12,600 | $3.08 | $38.81K | 72,400 |
| Ron Squarer Director | Jun 3, 2026 | Tax withholding | −15,196 | $3.08 | $46.80K | 123,431 |
| Peter Hug Director | Jun 3, 2026 | Tax withholding | −2,156 | $3.08 | $6.64K | 263,344 |
| Viviane Monges Director | Jun 3, 2026 | Tax withholding | −2,596 | $3.08 | $8.00K | 186,447 |
| Jean-Pierre Bizzari Director | Jun 3, 2026 | Tax withholding | −12,600 | $3.08 | $38.81K | 139,302 |
| Robert Azelby Director | Jun 3, 2026 | Tax withholding | −12,600 | $3.08 | $38.81K | 112,805 |
| Victor Sandor Director | Jun 3, 2026 | Tax withholding | −12,600 | $3.08 | $38.81K | 140,686 |
| Timothy Coughlin Director | Jun 1, 2026 | Award | +45,000 | – | – | 85,000 |
| Ron Squarer Director | Jun 1, 2026 | Award | +45,000 | – | – | 138,627 |
| Peter Hug Director | Jun 1, 2026 | Award | +45,000 | – | – | 265,500 |
| Viviane Monges Director | Jun 1, 2026 | Award | +45,000 | – | – | 189,043 |
| Jean-Pierre Bizzari Director | Jun 1, 2026 | Award | +45,000 | – | – | 151,902 |
| Robert Azelby Director | Jun 1, 2026 | Award | +45,000 | – | – | 125,405 |
| Victor Sandor Director | Jun 1, 2026 | Award | +45,000 | – | – | 153,286 |
| RedCo II Master Fund, L.P. 10% owner | Apr 2, 2026 | Sale | −2,529,491 | $3.28 | $8.30M | 10,265,297 |
| RedCo II Master Fund, L.P. 10% owner | Apr 2, 2026 | Sale | −2,634,506 | $3.28 | $8.64M | 12,666,731 |
| RedCo II Master Fund, L.P. 10% owner | Apr 1, 2026 | Sale | −169,265 | $3.80 | $643.21K | 15,301,237 |
| RedCo II Master Fund, L.P. 10% owner | Apr 1, 2026 | Sale | −162,517 | $3.80 | $617.56K | 12,794,788 |
| RedCo II Master Fund, L.P. 10% owner | Mar 31, 2026 | Sale | −188,407 | $3.75 | $706.53K | 12,957,305 |
| RedCo II Master Fund, L.P. 10% owner | Mar 31, 2026 | Sale | −196,229 | $3.75 | $735.86K | 15,470,502 |
| Lisa Michelle Kallebo Chief Accounting Officer | Feb 13, 2026 | Tax withholding | −5,433 | $3.99 | $21.68K | 128,224 |
| Lisa Michelle Kallebo Chief Accounting Officer | Feb 13, 2026 | Award | +62,900 | $3.99 | $250.97K | 133,657 |
| Jose Carmona Chief Financial Officer | Feb 13, 2026 | Tax withholding | −25,880 | $3.99 | $103.26K | 734,376 |
| Jose Carmona Chief Financial Officer | Feb 13, 2026 | Award | +271,600 | $3.99 | $1.08M | 760,256 |
| Peter J. Graham Chief Legal Officer | Feb 13, 2026 | Tax withholding | −33,294 | $3.99 | $132.84K | 620,540 |
| Peter J. Graham Chief Legal Officer | Feb 13, 2026 | Award | +294,800 | $3.99 | $1.18M | 653,834 |
| Mohamed Zaki Chief Medical Officer | Feb 13, 2026 | Award | +285,200 | $3.99 | $1.14M | 707,020 |
| Mohamed Zaki Chief Medical Officer | Feb 13, 2026 | Tax withholding | −24,603 | $3.99 | $98.17K | 682,417 |
| Ameet Mallik Chief Executive Officer, Director | Feb 13, 2026 | Award | +900,000 | $3.99 | $3.59M | 1,550,000 |
| Ameet Mallik Chief Executive Officer, Director | Feb 13, 2026 | Tax withholding | −103,231 | $3.99 | $411.89K | 1,446,769 |
| Ameet Mallik Chief Executive Officer, Director | Dec 6, 2025 | Tax withholding | −233,146 | $3.29 | $767.05K | 1,319,101 |
| Lisa Michelle Kallebo Chief Accounting Officer | Dec 6, 2025 | Tax withholding | −7,140 | $3.29 | $23.49K | 70,757 |
| Jose Carmona Chief Financial Officer | Dec 6, 2025 | Tax withholding | −53,236 | $3.29 | $175.15K | 488,656 |
| Mohamed Zaki Chief Medical Officer | Dec 6, 2025 | Tax withholding | −41,068 | $3.29 | $135.11K | 421,820 |
| Peter J. Graham Chief Legal Officer | Dec 6, 2025 | Tax withholding | −49,508 | $3.29 | $162.88K | 359,034 |
| Ron Squarer Director | Jun 13, 2025 | Tax withholding | −15,184 | $3.58 | $54.36K | 93,627 |
| Victor Sandor Director | Jun 13, 2025 | Tax withholding | −12,600 | $3.58 | $45.11K | 108,286 |
| Jean-Pierre Bizzari Director | Jun 13, 2025 | Tax withholding | −12,600 | $3.58 | $45.11K | 106,902 |
| Peter Hug Director | Jun 13, 2025 | Tax withholding | −2,144 | $3.58 | $7.68K | 220,500 |
| Viviane Monges Director | Jun 13, 2025 | Tax withholding | −2,584 | $3.58 | $9.25K | 144,043 |
| Robert Azelby Director | Jun 13, 2025 | Tax withholding | −12,600 | $3.58 | $45.11K | 80,405 |
| Viviane Monges Director | Jun 3, 2025 | Award | +40,000 | – | – | 146,627 |
| Victor Sandor Director | Jun 3, 2025 | Award | +40,000 | – | – | 120,886 |
| Peter Hug Director | Jun 3, 2025 | Award | +40,000 | – | – | 222,644 |
| Robert Azelby Director | Jun 3, 2025 | Award | +40,000 | – | – | 93,005 |
| Jean-Pierre Bizzari Director | Jun 3, 2025 | Award | +40,000 | – | – | 119,502 |
| Ron Squarer Director | Jun 3, 2025 | Award | +40,000 | – | – | 108,811 |
| Timothy Coughlin Director | Jun 3, 2025 | Award | +40,000 | – | – | 40,000 |
| Thomas Pfisterer – | May 15, 2025 | Other | −451,856 | – | – | 173,899 |
| Hans Peter Wild 10% owner | May 15, 2025 | Other | +9,788,944 | – | – | 9,788,944 |
| Ameet Mallik Chief Executive Officer, Director | May 6, 2025 | Tax withholding | −26,758 | $1.29 | $34.52K | 1,552,247 |
| Peter J. Graham Chief Legal Officer | Feb 13, 2025 | Award | +220,000 | $1.61 | $354.20K | 408,542 |
| Jose Carmona Chief Financial Officer | Feb 13, 2025 | Award | +240,000 | $1.61 | $386.40K | 541,892 |
| Lisa Michelle Kallebo Chief Accounting Officer | Feb 13, 2025 | Award | +41,900 | $1.61 | $67.46K | 77,897 |
| Ameet Mallik Chief Executive Officer, Director | Feb 13, 2025 | Award | +650,000 | $1.61 | $1.05M | 1,579,005 |
| Mohamed Zaki Chief Medical Officer | Feb 13, 2025 | Award | +230,000 | $1.61 | $370.30K | 462,888 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ADC Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,900 shares on Sep 18, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Victor Sandor Director | Jun 18, 2024 | 6,995 | $20.22K | Jun 17, 2024 | Vesting of Restricted Share Unit Grant |
| Jean-Pierre Bizzari Director | Jun 18, 2024 | 6,995 | $20.22K | Jun 17, 2024 | Vesting of Restricted Share Unit Grant |
| Ron Squarer Director | Jun 18, 2024 | 6,995 | $20.22K | Jun 17, 2024 | Vesting of Restricted Share Unit Grant |
| Robert Azelby Director | Jun 18, 2024 | 6,995 | $20.22K | Jun 17, 2024 | Vesting of Restricted Share Unit Grant |
| Ameet Mallik Officer and Director | May 7, 2024 | 29,731 | $134.19K | May 7, 2024 | Vesting of Restricted Share Unit Grant |
See a number that looks wrong?